Skip to content

CalAmp CAMP Current ratio

Current ratio at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.6×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
+0.6×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
27.1×-3.9×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
0.5×-1.0×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
14×+8.7×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
10.4×+8.7×

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×

Where this comes from

Calculated from CalAmp’s reported figures.

Based on the most recent quarter.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's current ratio?
CalAmp (CAMP) reported current ratio of 6.1× in Q1 2026.
How has CalAmp's current ratio changed year-over-year?
CalAmp's current ratio decreased by 23.4% year-over-year, from 8× to 6.1×.
What is the long-term trend for CalAmp's current ratio?
Over 2 years (2023 to 2025), CalAmp's current ratio has grown at a 19.8% compound annual growth rate (CAGR), from 5.1× to 7.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.